Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × rrCLL × Lymphoid × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma 723 Lymphoma, Non-Hodgkin 656 Precursor Cell Lymphoblastic Leukemia-Lymphoma 579 Leukemia, Lymphocytic, Chronic, B-Cell 555 Lymphoma, Large B-Cell, Diffuse 438 Lymphoma, Follicular 415 Lymphoma, Mantle-Cell 344 Burkitt Lymphoma 305 Leukemia 301 Leukemia, Myeloid, Acute 295 Hodgkin Disease 293 Lymphoma, B-Cell 279 Lymphoma, B-Cell, Marginal Zone 266 Recurrence 245 Multiple Myeloma 204 Neoplasms 198 Lymphoma, T-Cell, Cutaneous 171 Myelodysplastic Syndromes 168 Lymphoma, Large-Cell, Immunoblastic 160 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 159 Waldenstrom Macroglobulinemia 145 Lymphoma, Large-Cell, Anaplastic 142 Mycosis Fungoides 132 Sezary Syndrome 119 Immunoblastic Lymphadenopathy 108 Blast Crisis 92 Hematologic Neoplasms 91 Lymphoma, T-Cell, Peripheral 86 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 86 Lymphoma, T-Cell 82

Interventions

pembrolizumab 1 dinaciclib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02684617 2021-03-01

KEYNOTE-155

Merck Sharp & Dohme LLC

Phase 1 Terminated

75 enrolled 17 charts

rrCLL

Data powered by HemOnc (CC BY 4.0) Colophon ⚡